Pharmaceutical - Anti-virals, AbbVie

Filter

Current filters:

Anti-viralsAbbVie

Popular Filters

AbbVie issues earnings-per-share guidance up 30% for 2015

AbbVie issues earnings-per-share guidance up 30% for 2015

12-01-2015

US drugmaker AbbVie has issued updated guidance about its expected earnings in 2015.

AbbVieAnti-viralsFinancialHumiraPharmaceuticalUSAViekira Pak

Express Scripts says AbbVie’s Viekira Pak to be exclusive option for genotype 1 hepatitis C

Express Scripts says AbbVie’s Viekira Pak to be exclusive option for genotype 1 hepatitis C

22-12-2014

Express Scripts today announced an update to its National Preferred Formulary that will significantly…

AbbVieAnti-viralsExpress ScriptsGilead SciencesHarvoniPharmaceuticalPricingSovaldiUSAViekira Pak

FDA approves fourth hepatitis C drug, AbbVie’s Viekira Pak

FDA approves fourth hepatitis C drug, AbbVie’s Viekira Pak

20-12-2014

The US Food and Drug Administration on Friday confirmed the much anticipated approval of US pharma company…

AbbVieAnti-viralsPharmaceuticalRegulationUSAViekira Pak

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

01-12-2014

US drugmaker AbbVie and the Medicines Patent Pool have agreed a licensing agreement for lopinavir and…

AbbVieAnti-viralsLopinavirPharmaceuticalResearchRitonavir TabletsUSA

EMA unit backs new hep C drugs Exviera and Viekirax from AbbVie

EMA unit backs new hep C drugs Exviera and Viekirax from AbbVie

21-11-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AbbVieAnti-viralsEuropeExvieraPharmaceuticalRegulationViekirax

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

11-11-2014

US pharma company AbbVie got a boost for its upcoming hepatitis C treatment regimen, with the company…

AbbVieAnti-viralsPharmaceuticalResearchUSA

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

17-06-2014

US drugmaker AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational,…

AbbVieAnti-viralsPharmaceuticalRegulationRitonavir TabletsUSA

AbbVie opens expanded manufacturing facility in Ireland

AbbVie opens expanded manufacturing facility in Ireland

03-06-2014

The chairman and chief of US drugmaker AbbVie, Richard Gonzalez, accompanied by other senior executives,…

AbbVieAnti-viralsFinancialIrelandPharmaceuticalProduction

AbbVie files for Canadian approval of all-oral, interferon-free hepatitis C therapy

22-05-2014

US drugmaker AbbVie has filed a New Drug Submission to Health Canada seeking approval for its investigational,…

AbbVieAnti-viralsCanadaPharmaceuticalRegulation

AbbVie files for EU marketing approval for its all-oral, interferon-free hepatitis C therapy

AbbVie files for EU marketing approval for its all-oral, interferon-free hepatitis C therapy

08-05-2014

US drugmaker AbbVie has submitted marketing authorization applications to the European Medicines Agency…

AbbVieAnti-viralsPharmaceuticalRegulationUSA

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

28-11-2013

In further legal action against drugmakers allegedly over pricing AIDS drugs in the USA, the AIDS Healthcare…

Abbott LaboratoriesAbbVieAnti-viralsKaletra TabletsLegalNorth AmericaNorvirPharmaceuticalPricing

US FDA grants "Breakthrough" status for AbbVie's HCV regimen

06-05-2013

US drugmaker AbbVie (NYSE: ABBV) says that its investigational direct-acting antiviral (DAA) combination…

AbbVieAnti-viralsPharmaceuticalRegulationResearch

Back to top